Literature DB >> 950302

[Technical experience with 8-methoxypsoralen photochemotherapy in common psoriasis].

C Hofmann, G Plewig, O Braun-Falco.   

Abstract

Photochemotherapy with 8-MOP und UV-A is a modality to treat psoriasis vulgaris successfully. Technical experiences with three types of machines, a horizontal box with Sylvania fluorescent lamps, a stand-up box, and a hand-foot-box with Osram fluorescent lamps are reported. Oral and topical 8-MOP applications are compared for these three types of boxes. Disadvantages of the oral or topical 8-MOP applications are compiled. Oral 8-MOP is superior to the topical treatment in both the stand-up and the horizontal box. The following technical features are discussed: Minimal phototoxic dose, photopigmentation index, radiation-dose, time increments during treatment, maintenance therapy, and UV-A meters.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950302

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  5 in total

1.  [Semen analysis under photochemotherapy (PUVA-therapy) (author's transl)].

Authors:  W B Schill; C Hofmann; G Plewig
Journal:  Arch Dermatol Res       Date:  1979-03-31       Impact factor: 3.017

2.  Professor Dr. Dr. h. c. Otto Braun-Falco.

Authors: 
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  [Histopathology and histochemistry of psoriasis under photochemotherapy (author's transl)].

Authors:  O Braun-Falco; C Hofmann; G Plewig
Journal:  Arch Dermatol Res       Date:  1977-01-31       Impact factor: 3.017

4.  Photoallergic dermatitis from 8-methoxypsoralen.

Authors:  G Plewig; C Hofmann; O Braun-Falco
Journal:  Arch Dermatol Res       Date:  1978-04-07       Impact factor: 3.017

5.  In vivo autoradiography and planimetry of epidermis in psoriatics under PUVA-therapy.

Authors:  C Hofmann; M Landthaler; G Plewig; O Braun-Falco
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.